nach oben

Clinical and Translational Oncology

Erschienen in:

23.11.2020 | Research Article

Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma

verfasst von: I. C. Barıs, S. Hacıoglu, N. S. Turk, G. O. Cetın, S. Zencır, G. Bagcı, V. Caner

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Aims

Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive lymphoma. This study was designed to compare epigenetic alterations observed in Enhancer of Zeste Homolog 2 (EZH2)-target genes between plasma-derived exosomes and primary tumors in DLBCL patients.

Main methods

Exosomes were isolated from plasma of 21 DLBCL patients and 21 controls. We analyzed the methylation status of the target genes using methylation-specific PCR. We also examined whether the exosomes and the tumor samples contained transcripts of the target genes.

Key findings

We found that CDKN2A and CDKN2B were methylated in both plasma exosomes and primary tumor tissue samples. None of the transcripts were found in the exosomes except CDKN1B which was expressed in 8 (38%) of the exosome samples.

Significance

This study showed that plasma exosomes might preferably package certain target molecules from primary tumors and the exosomes containing dual methylated DNAs of CDKN2A and CDKN2B, or CDKN1B transcript may contribute to DLBCL pathogenesis.

Republic of Turkey, Ministry of Health, Cancer Statistics Yearbook, https://www.sbu.saglik.gov.tr/Ekutuphane/.../saglikistatistikleriyilligi2015.pdf. 2015.

Miao Y, Medeiros LJ, Li Y, Li J, Young KH. Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol. 2019;16(10):634–52. https://doi.org/10.1038/s41571-019-0225-1.CrossRefPubMed

Pasqualucci L. Molecular pathogenesis of germinal center-derived B cell lymphomas. Immunol Rev. 2019;288(1):240–61. https://doi.org/10.1111/imr.12745.CrossRefPubMed

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay K, Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;15:1396–407. https://doi.org/10.1056/NEJMoa1801445.CrossRef

Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, Ménard AL, Etancelin P, Bertrand P, Dubois S, Alcantara M, Bastard C, Tilly H, Jardin F. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosome Cancer. 2014;2:144–53. https://doi.org/10.1002/gcc.22126.CrossRef

Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, Elemento O. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010;116:5247–55. https://doi.org/10.1182/blood-2010-04-280149.CrossRefPubMedPubMedCentral

Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, Bond VC, Borràs FE, Breakefield X, Budnik V, Buzas E, Camussi G, Clayton A, Cocucci E, Falcon-Perez JM, Gabrielsson S, Gho YS, Gupta D, Harsha HC, Hendrix A, Hill AF, Inal JM, Jenster G, Krämer-Albers EM, Lim SK, Llorente A, Lötvall J, Marcilla A, Mincheva-Nilsson L, Nazarenko I, Nieuwland R, Nolte-'t Hoen EN, Pandey A, Patel T, Piper MG, Pluchino S, Prasad TS, Rajendran L, Raposo G, Record M, Reid GE, Sánchez-Madrid F, Schiffelers RM, Siljander P, Stensballe A, Stoorvogel W, Taylor D, Thery C, Valadi H, van Balkom BW, Vázquez J, Vidal M, Wauben MH, Yáñez-Mó M, Zoeller M, Mathivanan S, Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012;12:e1001450. https://doi.org/10.1371/journal.pbio.1001450.CrossRef

Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;6:1226–322. https://doi.org/10.1016/j.cell.2016.01.043.CrossRef

Maas SLN, Breakefield XO. Weaver extracellular vesicles: unique intercellular delivery vehicles. Trends Cell Biol. 2017;3:172–88. https://doi.org/10.1016/j.tcb.2016.11.003.CrossRef

10.

Kalluri R, LeBleu VS. Discovery of double-stranded genomic DNA in circulating exosomes. Cold Spring Harb Symp Quant Biol. 2016;81:275–80. https://doi.org/10.1101/sqb.2016.81.030932.CrossRefPubMed

11.

Bortoluzzi S, Lovisa F, Gaffo E, Mussolin L. Small RNAs in circulating exosomes of cancer patients: a minireview. High Throughput. 2017;4:13. https://doi.org/10.3390/ht6040013.CrossRef

12.

Chen Z, You L, Wang L, Huang X, Liu H, Wei JY, Zhu L, Qian W. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. J Exp Clin Cancer Res. 2018;1:190. https://doi.org/10.1186/s13046-018-0863-7.CrossRef

13.

Koch R, Demant M, Aung T, Diering N, Cicholas A, Chapuy B, Wenzel D, Lahmann M, Güntsch A, Kiecke C, Becker S, Hupfeld T, Venkataramani V, Ziepert M, Opitz L, Klapper W, Trümper L, Wulf GG. Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood. 2014;14:2189–98.CrossRef

14.

Feng Y, Zhong M, Zeng S, Wang L, Liu P, Xiao X, Liu Y. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics. 2019;1:35–51. https://doi.org/10.2217/epi-2018-0123.CrossRef

15.

Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F. The ISTH SSC Workshop Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost. 2013. https://doi.org/10.1111/jth.12207.CrossRefPubMedPubMedCentral

16.

Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, Nolte-'t Hoen EN, Piper MG, Sivaraman S, Skog J, Théry C, Wauben MHFH. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013. https://doi.org/10.1111/jth.12207.CrossRefPubMedPubMedCentral

17.

McDonald MK, Capasso KE, Ajit SK. Purification and microRNA profiling of exosomes derived from blood and culture media. J Vis Exp. 2013;76:e50294. https://doi.org/10.3791/50294.CrossRef

18.

Cvjetkovic A, Lötvall J, Lässer C. The influence of rotor type and centrifugation time on the yield and purity of extracellular vesicles. J Extracell Vesicles. 2014;3:23111. https://doi.org/10.3402/jev.v3.23111.CrossRef

19.

Lotvall J, Hill AF, Hochberg F, Buzas EI, Di D, Vizio C, Gardiner YS, Gho IV, Kurochkin S, Mathivanan PQ, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913. https://doi.org/10.3402/jev.v3.26913.CrossRefPubMed

20.

Taylor DD, Gerçel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005;2:305–11. https://doi.org/10.1038/sj.bjc.6602316.CrossRef

21.

Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, Kim MK, Kim YG, Jang JY, Kim CW. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS ONE. 2013;1:e84256. https://doi.org/10.1371/journal.pone.0084256.CrossRef

22.

Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, Hoshino A, Brazier H, Xiang J, Williams C, Rodriguez-Barrueco R, Silva JM, Zhang W, Hearn S, Elemento O, Paknejad N, Manova-Todorova K, Welte K, Bromberg J, Peinado H, Lyden D. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res. 2014;6:766–76. https://doi.org/10.1038/cr.2014.44.CrossRef

23.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;1:275–82. https://doi.org/10.1182/blood-2003-05-1545.CrossRef

24.

Watanabe M, Nakahata S, Hamasaki M, Saito Y, Kawano Y, Hidaka T, Yamashita K, Umeki K, Taki T, Taniwaki M, Okayama A, Morishita K. Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines. J Virol. 2010;14:6966–77. https://doi.org/10.1128/JVI.00073-10.CrossRef

25.

Park KH, Seol JY, Kim TY, Yoo CG, Kim YW, Han SK, Shim YS, Lee CT. An adenovirus expressing mutant p27 showed more potent antitumor effects than adenovirus-p27 wild type. Cancer Res. 2001;16:6163–9.

26.

Psofaki V, Kalogera C, Tzambouras N, Stephanou D, Tsianos E, Seferiadis K, Kolios G. Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas. World J. Gastroenterol. 2010;28:3553–600. https://doi.org/10.3748/wjg.v16.i28.3553.CrossRef

27.

Shiozawa E, Takimoto M, Makino R, Adachi D, Saito B, Yamochi-Onizuka T, Yamochi T, Shimozuma J, Maeda T, Kohno Y, Kawakami K, Nakamaki T, Tomoyasu S, Shiokawa A, Ota H. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk. Res. 2006;7:859–67. https://doi.org/10.1016/j.leukres.2005.11.004.CrossRef

28.

Cetin GO, Baris IC, Caner V, Sarikepe B, Sen Turk N, Tepeli E, Hacioglu S, Sari I, Bagci G, Keskin A. Mutational status of EZH2 and CD79B hot spots in mature B-cell non-Hodgkin's lymphomas: novel CD79B variations have been revealed. Eur Rev Med Pharmacol Sci. 2016;5:830–6.

29.

Galindo-Hernandez O, Villegas-Comonfort S, Candanedo F, González-Vázquez MC, Chavez-Ocaña S, Jimenez-Villanueva X, Sierra-Martinez M, Salazar EP. Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients. Arch Med Res. 2013;3:208–14. https://doi.org/10.1016/j.arcmed.2013.03.002.CrossRef

30.

Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H, Szpurek D, Nowakowski A, Spaczynski M, Baranowski W, Whiteside TL. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol Obstet (Sunnyvale). 2013;29:3. https://doi.org/10.4172/2161-0932.S4-003.CrossRef

31.

Yeh YY, Ozer HG, Lehman AM, Maddocks K, Yu L, Johnson AJ, Byrd JC. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. 2015;21:3297–305. https://doi.org/10.1182/blood-2014-12-618470.CrossRef

32.

Eijndhoven MAJ, Zijlstra JM, Groenewegen NJ, Drees EE, Niele S, Baglio SR, Koppers-Lalic D, Voorn H, Libregts S, Wauben MHM, Menezes RX, Weering JRT, Nieuwland R, Visser L, Berg A, Jong D, Pegtel DM. Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight. 2016;19:e89631. https://doi.org/10.1172/jci.insight.89631.CrossRef

33.

Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-β1. Haematologica. 2011;9:1302–9. https://doi.org/10.3324/haematol.2010.039743.CrossRef

34.

He M, Crow J, Roth M, Zeng Y, Godwin AK. Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab. Chip. 2014;19:3773–800. https://doi.org/10.1039/c4lc00662c.CrossRef

35.

Le M, Fernandez-Palomo C, McNeill FE, Seymour CB, Rainbow AJ, Mothersill CE. Exosomes are released by bystander cells exposed to radiation-induced biophoton signals: reconciling the mechanisms mediating the bystander effect. PLoS ONE. 2017;3:e0173685. https://doi.org/10.1371/journal.pone.0173685.CrossRef

36.

McCready J, Sims JD, Chan D, Jay DG. Secretion of extracellular hsp90α via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer. 2010;10:294. https://doi.org/10.1186/1471-2407-10-294.CrossRefPubMedPubMedCentral

37.

Rutherford SC, Sawh S, Saxena A, Ishii J, Dominguez MD, Chambwe N, Lopes EC, Agirre X, Doron B, Rita S. Characterization of DLBCL-derived exosomes and investigation of their biological properties. Blood. 2014;124:3021. https://doi.org/10.1182/blood.V124.21.3021.3021.CrossRef

38.

Speicher MR, Pantel K. Tumor signatures in the blood. Nat Biotechnol. 2014;5:441–3. https://doi.org/10.1038/nbt.2897.CrossRef

39.

Jin Y, Chen K, Wang Z, Wang Y, Liu J, Lin L, Shao Y, Gao L, Yin H, Cui C, Tan Z, Liu L, Zhao C, Zhang G, Jia R, Du L, Chen Y, Liu R, Xu J, Hu X, Wang Y. DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer. 2016;16:753. https://doi.org/10.1186/s12885-016-2783-2.CrossRefPubMedPubMedCentral

40.

Kahlert C, Melo SA, Protopopov A, Tang J, Seth S, Koch M, Zhang J, WeitzChin JL, Futreal A, Kalluri R. Identification of double stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic. Cancer J. Biol. Chem. 2014;7:3869–75. https://doi.org/10.1074/jbc.C113.532267.CrossRef

41.

Wang L, Li Y, Guan X, Zhao J, Shen L, Liu J. Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma. Mol Cancer. 2018;1:128. https://doi.org/10.1186/s12943-018-0876-z.CrossRef

42.

Shiozawa E, Takimoto M, Makino R, Adachi D, Saito B, Yamochi-Onizuka T, Yamochi T, Shimozuma J, Maeda T, Kohno Y, Kawakami K, Nakamaki T, Tomoyasu S, Shiokawa A, Ota H. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk Res. 2006;7:859–67. https://doi.org/10.1016/j.leukres.2005.11.004.CrossRef

43.

Guney S, Jardin F, Bertrand P, Mareschal S, Parmentier F, Picquenot JM, Tilly H, Bastard C. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes. Genes Chromosomes Cancer. 2012;9:858–67. https://doi.org/10.1002/gcc.21970.CrossRef

44.

Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol. 2008;10:1774–866. https://doi.org/10.1093/annonc/mdn374.CrossRef

45.

Krajnović M, Jovanović MP, Mihaljević B, Anđelić B, Tarabar O, Knežević-Ušaj S, Krtolica K. Hypermethylation of p15 gene in diffuse - large B-cell lymphoma: association with less aggressiveness of the disease. Clin Transl Sci. 2014;5:384–90. https://doi.org/10.1111/cts.12162.CrossRef

46.

Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review. Int J Cancer. 2011;128:1080–94. https://doi.org/10.1002/ijc.25432.CrossRefPubMedPubMedCentral

47.

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE. 2008;3:e3698. https://doi.org/10.1371/journal.pone.0003698.CrossRefPubMedPubMedCentral

48.

Chambwe N, Kormaksson M, Geng H, De S, Michor F, Johnson NA, Morin RD, Scott DW, Godley LA, Gascoyne RD, Melnick A, Campagne F, Shaknovich R. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014;11:1699–708. https://doi.org/10.1182/blood-2013-07-509885.CrossRef

49.

Zhou Z, Gao J, Popovic R, Wolniak K, Parimi V, Winter JN, Licht JD, Chen YH. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma. 2015;10:2895–901. https://doi.org/10.3109/10428194.2015.1006220.CrossRef

50.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;5:677–92. https://doi.org/10.1016/j.ccr.2013.04.011.CrossRef

51.

Caganova M, Carrisi C, Varano G, Mainoldi F, Zanardi F, Germain PL, George L, Alberghini F, Ferrarini L, Talukder AK, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J. Clin. Invest. 2013;123:5009–222. https://doi.org/10.1172/JCI70626.CrossRefPubMedPubMedCentral

52.

Hong BS, Cho JH, Kim H, Choi EJ, Rho S, Kim J, Kim JH, Choi DS, Kim YK, Hwang D, Gho YS. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genom. 2009;10:556. https://doi.org/10.1186/1471-2164-10-556.CrossRef

53.

Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves MWT, Curr BS Jr, Carter AM, Krichevsky XOB. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;12:1470–6. https://doi.org/10.1038/ncb1800.CrossRef

54.

Bolukbasi MF, Mizrak A, Ozdener GB, Madlener S, Ströbel T, Erkan EP, Fan JB, Breakefield XO, Saydam O. miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in Microvesicles. Mol Ther Nucleic Acids. 2012;1:e10. https://doi.org/10.1038/mtna.2011.2.CrossRefPubMedPubMedCentral

55.

Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. J. Cell Physiol. 2015;3:504–9. https://doi.org/10.1002/jcp.24819.CrossRef

Titel: Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma
verfasst von: I. C. Barıs
S. Hacıoglu
N. S. Turk
G. O. Cetın
S. Zencır
G. Bagcı
V. Caner
Publikationsdatum: 23.11.2020
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 6/2021
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02504-6

Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence

Open Access
Review Article

The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Research Article

TWIST1 upregulation affects E-cadherin expression in brain metastases

Research Article

Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma

Research Article

ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma

Open Access
Research Article

Consensus and recommendations on vaginal-cuff Brachytherapy of the Spanish Brachytherapy Groups of SEOR and SEFM

Research Article

Neu im Fachgebiet Onkologie

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

20.04.2025
Melanom
Nachrichten

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

17.04.2025
AAN-Jahrestagung 2025
Kongressbericht

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

17.04.2025
DGP 2025
Kongressbericht

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

17.04.2025
Koloskopie
Nachrichten

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Expression and DNA methylation profiles of EZH2-target genes in plasma exosomes and matched primary tumor tissues of the patients with diffuse large B-cell lymphoma

Abstract